ALT 0.00% 0.1¢ analytica limited

Ann: Change in directors interest notice - 3, page-24

  1. 372 Posts.
    lightbulb Created with Sketch. 49
    siren4, I think anything is possible in the sharemarket game, but negotiations are in progress, including for the ASB, and are well within a reasonable time frame.
    My faith is in Corr. A former Dean so good at the theory Pfizer hired him for a senior position. Then, putting theory into practice, he founded his own very successful company.

    The business model of Auven Therapuetics is to buy or take a controlling stake in newish products/businesses, get them ready for commercialization, then do a deal providing a royalty stream. Now he runs Inov8, an investment fund attached to the Tech Park at the Uni of Virgin Islands, which does a similar thing. His integrity is & has to be impeccable. And that's just a summary of his CV.
    He knows what he's doing, and I note his involvement with PeriCoach came after it was obvious sales were floundering. He was there when the decision was made to stop spending resources on sales & focus on the deal.

    Alt has stated majors want our product but requested V3. It is finished although there will be software upgrades, hence the subscription model. A partner might want to alter design aspects.
    There is no competitor that comes remotely close to the quality of PeriCoach let alone have Govt. approvals. We have it for 2 indications.
    A variety of opinions are expressed on this thread, a good thing if they're honest and well stated, and in essence these posts express individual opinions on risk & reward, which is all I'm doing.

    Obviously women would prefer not to have to use it; but to what extent is the 'invasive nature' a deterrent.
    Being male it doesn't sit right for me to guess (thx for posting Jsmama) so I look for logical clues.
    - Designed by a female.
    - Who won an award for it; not her only award.
    - Who now leads product development.
    - Though m'ment and board are male they have Dr as a title so I don't doubt their objectivity.
    - Overwhelming positive feedback from mostly female clinicians.
    - Recommended by mostly female clinicians.
    - Successful use by women to date.
    - Feedback from female bloggers for what it's worth.
    - The market in segments: Severe - they will use it. Moderate, & mild to no problem, guess work; BUT there are good reasons for most adult women to try it, and our partner will be highly skilled at driving acceptance. And several have pointed out we only need a small fraction of multiple markets for big $, which parties currently negotiating also know.
    - It's not a mouse! It's a small medtech device for a part of female anatomy of importance to them.
    It reduces symptoms or risk of. It can reduce need for or risk of surgery. Usage is for a few minutes at a time, and certainly not daily for most.
    Women are adept at discretion. They accept the invasive nature of tampons, probing physicians, dicks (sorry mods, I mean penises). For decades there's been something called something called suppositories - if any don't know what they are ask Tony Abbott. And it just so happens that the vagina is where babies come out of; usually.
    - There are female shareholders; including MM's wife.
    - It will be made in USA by a name brand.
    That's enough for me.
 
watchlist Created with Sketch. Add ALT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.